Corvus Pharmaceuticals, Inc. Operating Lease, Payments
Corvus Pharmaceuticals, Inc. (CRVS) reported Operating Lease, Payments of $199.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2026-06-30 was $199.00K, a 91.35% increase year-over-year.
- Corvus Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2026-03-31 was $188.00K.
- Corvus Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2025-09-30 was $157.00K, a 66.81% decline year-over-year.
- Corvus Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2025-06-30 was $104.00K, a 78.01% decline year-over-year.
- Corvus Pharmaceuticals, Inc. operating lease, payments for fiscal 2023 was $1.84M, a 8.50% increase from fiscal 2022.
- Corvus Pharmaceuticals, Inc. operating lease, payments for fiscal 2022 was $1.70M, a 3.04% increase from fiscal 2021.
- Corvus Pharmaceuticals, Inc. operating lease, payments for fiscal 2021 was $1.65M, a 9.23% increase from fiscal 2020.
- Corvus Pharmaceuticals, Inc. operating lease, payments for fiscal 2020 was $1.51M, a 3.93% increase from fiscal 2019.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $199.00K 10-Q · filed 2026-08-06 | $387.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $188.00K 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | $157.00K 10-Q · filed 2025-11-04 | $261.00K derived: sum of 2 quarters · filed 2026-08-06 | $261.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $104.00K 10-Q · filed 2026-08-06 | $104.00K 10-Q · filed 2026-08-06 | ||
| 2024-09-30 | $473.00K 10-Q · filed 2024-11-12 | $946.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.42M 10-Q · filed 2024-11-12 | $1.88M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $473.00K 10-Q · filed 2024-08-06 | $946.00K 10-Q · filed 2024-08-06 | $1.41M derived: sum of 3 quarters · filed 2024-08-06 | $1.87M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | $473.00K 10-Q · filed 2024-05-07 | $934.00K derived: sum of 2 quarters · filed 2024-05-07 | $1.39M derived: sum of 3 quarters · filed 2024-11-12 | $1.85M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | $461.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $920.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.38M derived: sum of 3 quarters · filed 2024-11-12 | $1.84M 10-K · filed 2024-03-19 |
| 2023-09-30 | $459.00K 10-Q · filed 2024-11-12 | $919.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.38M 10-Q · filed 2024-11-12 | $1.81M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $460.00K 10-Q · filed 2024-08-06 | $919.00K 10-Q · filed 2024-08-06 | $1.35M derived: sum of 3 quarters · filed 2024-08-06 | $1.78M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $459.00K 10-Q · filed 2024-05-07 | $889.00K derived: sum of 2 quarters · filed 2024-05-07 | $1.32M derived: sum of 3 quarters · filed 2024-05-07 | $1.75M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $430.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $863.00K derived: sum of 2 quarters · filed 2024-03-19 | $1.30M derived: sum of 3 quarters · filed 2024-03-19 | $1.70M 10-K · filed 2024-03-19 |
| 2022-09-30 | $433.00K 10-Q · filed 2023-11-07 | $866.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.26M 10-Q · filed 2023-11-07 | $1.70M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $433.00K 10-Q · filed 2023-08-08 | $832.00K 10-Q · filed 2023-08-08 | $1.27M derived: sum of 3 quarters · filed 2024-03-19 | $1.68M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $433.00K 10-Q · filed 2023-05-08 | $838.00K derived: sum of 2 quarters · filed 2024-03-19 | $1.25M derived: sum of 3 quarters · filed 2024-03-19 | $1.66M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $818.00K derived: sum of 2 quarters · filed 2024-03-19 | $1.23M derived: sum of 3 quarters · filed 2024-03-19 | $1.65M 10-K · filed 2024-03-19 |
| 2021-09-30 | $413.00K 10-Q · filed 2022-11-03 | $826.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.24M 10-Q · filed 2022-11-03 | $1.61M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $413.00K 10-Q · filed 2022-08-08 | $827.00K 10-Q · filed 2022-08-08 | $1.20M derived: sum of 3 quarters · filed 2023-03-28 | $1.58M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $413.00K 10-Q · filed 2022-05-05 | $787.00K derived: sum of 2 quarters · filed 2023-03-28 | $1.16M derived: sum of 3 quarters · filed 2023-03-28 | $1.54M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $751.00K derived: sum of 2 quarters · filed 2023-03-28 | $1.13M derived: sum of 3 quarters · filed 2023-03-28 | $1.51M 10-K · filed 2023-03-28 |
| 2020-09-30 | $377.00K 10-Q · filed 2021-11-01 | $754.00K derived: sum of 2 quarters · filed 2021-11-01 | $1.13M 10-Q · filed 2021-11-01 | $1.50M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $377.00K 10-Q · filed 2021-08-02 | $755.00K 10-Q · filed 2021-08-02 | $1.12M derived: sum of 3 quarters · filed 2022-03-10 | $1.48M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $377.00K 10-Q · filed 2021-04-29 | $742.00K derived: sum of 2 quarters · filed 2022-03-10 | $1.10M derived: sum of 3 quarters · filed 2022-03-10 | $1.48M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $728.00K derived: sum of 2 quarters · filed 2022-03-10 | $1.10M derived: sum of 3 quarters · filed 2022-03-10 | $1.45M 10-K · filed 2022-03-10 |
| 2019-09-30 | $363.00K 10-Q · filed 2020-10-29 | $733.00K derived: sum of 2 quarters · filed 2020-10-29 | $1.08M 10-Q · filed 2020-10-29 | $1.44M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $370.00K 10-Q · filed 2020-07-30 | $729.00K 10-Q · filed 2020-07-30 | $1.07M derived: sum of 3 quarters · filed 2021-03-25 | $1.42M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $359.00K 10-Q · filed 2020-04-30 | $705.00K derived: sum of 2 quarters · filed 2021-03-25 | $1.05M derived: sum of 3 quarters · filed 2021-03-25 | $1.39M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $346.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $689.00K derived: sum of 2 quarters · filed 2021-03-25 | $1.03M derived: sum of 3 quarters · filed 2021-03-25 | $1.39M 10-K · filed 2021-03-25 |
| 2018-09-30 | $343.00K 10-Q · filed 2019-10-29 | $686.00K derived: sum of 2 quarters · filed 2019-10-29 | $1.04M 10-Q · filed 2019-10-29 | |
| 2018-06-30 | $343.00K 10-Q · filed 2019-08-01 | $699.00K 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $356.00K 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $1.40M 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |